Delphine Shophie Courvoisier

Delphine Shophie Courvoisier

Auto-generated profile, based on publicly available information

Delphine Shophie Courvoisier

University of Geneva, Faculty of Medicine, Geneva, Switzerland; Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland; Quality of Care Division, Geneva University Hospitals, Geneva, Switzerland

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2011 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
DCDelphine S. Courvoisier
Delphine S. Courvoisier
CCChristophe Combescure
Christophe Combescure
TAThomas Agoritsas
Thomas Agoritsas
AGAngèle Gayet-Ageron
Angèle Gayet-Ageron
TPThomas V. Perneger
Thomas V. Perneger

3 November 2022 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
GFGeorge E Fragoulis
George E Fragoulis
Elena NikiphorouElena Nikiphorou
Elena Nikiphorou
MDMrinalini Dey
Mrinalini Dey
SZSizheng Steven Zhao
Sizheng Steven Zhao
DCDelphine Sophie Courvoisier
Delphine Sophie Courvoisier
KHKimme L Hyrich
Kimme L Hyrich
Objectives To develop EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in patients with autoimmune inflammatory rheumatic diseases (AIIRD). Methods An international Task Force (TF) (22 members/15 countries) formulated recommendations, supported by systematic literature review findings. Level of evidence and grade of recommendation were assigned for each recommendation. Level of agreement was provided anonymously by each TF member. Results Four overarching principles (OAP) and eight recommendations were developed. The OAPs highlight the need for infections to be discussed with patients and with other medical specialties, in accordance with national regulations. In addition to biologic/targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for which screening for latent tuberculosis (TB) should be performed, screening could be considered also before conventional synthetic DMARDs, glucocorticoids and immunosuppressants. Interferon gamma release assay should be preferred over tuberculin skin test, where available. Hepatitis B (HBV) antiviral treatment should be guided by HBV status defined prior to starting antirheumatic drugs. All patients positive for hepatitis-C-RNA should be referred for antiviral treatment. Also, patients who are non-immune to varicella zoster virus should be informed about the availability of postexposure prophylaxis should they have contact with this pathogen. Prophylaxis against Pneumocystis jirovecii seems to be beneficial in patients treated with daily doses >15–30 mg of prednisolone or equivalent for >2–4 weeks. Conclusions These recommendations provide guidance on the screening and prevention of chronic and opportunistic infections. Their adoption in clinical practice is recommended to standardise and optimise care to reduce the burden of opportunistic infections in people living with AIIRD.

1 May 2021 in Annals of Internal Medicine
Verified
Journal Article
Open access
MNMayssam Nehme
Mayssam Nehme
OBOlivia Braillard
Olivia Braillard
GAGabriel Alcoba
Gabriel Alcoba
SPSigiriya Aebischer Perone
Sigiriya Aebischer Perone
DCDelphine Courvoisier
Delphine Courvoisier
IGIdris Guessous
Idris Guessous

1 September 2021 in Annals of Internal Medicine
Verified
Journal Article
Open access
MNMayssam Nehme
Mayssam Nehme
OBOlivia Braillard
Olivia Braillard
FCFrançois Chappuis
François Chappuis
DCDelphine S Courvoisier
Delphine S Courvoisier
IGIdris Guessous
Idris Guessous
Coronavirus disease 2019 (COVID-19) can lead to long-term health effects. This article systematically characterizes the prevalence and longitudinal evolution of COVID-19 symptoms more than 7 months... Visual Prevalence of Symptoms More Than 7 Months After Symptomatic COVID-19. Coronavirus disease 2019 (COVID-19) can lead to long-term health effects. This article systematically character... Background: With millions of SARS-CoV-2 infections worldwide, increasing numbers of patients are coming forward with long-term clinical effects of the disease lasting several weeks to months. Objec...

15 June 2022 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
KLKim Lauper
Kim Lauper
MIMichele Iudici
Michele Iudici
DMDenis Mongin
Denis Mongin
SBSytske Anne Bergstra
Sytske Anne Bergstra
DCDenis Choquette
Denis Choquette
AFAxel Finckh
Axel Finckh
Background JAK-inhibitors (JAKi), recently approved in rheumatoid arthritis (RA), have changed the landscape of treatment choices. We aimed to compare the effectiveness of four current second-line therapies of RA with different modes of action, since JAKi approval, in an international collaboration of 19 registers. Methods In this observational cohort study, patients initiating tumour necrosis factor inhibitors (TNFi), interleukin-6 inhibitors (IL-6i), abatacept (ABA) or JAKi were included. We compared the effectiveness of these treatments in terms of drug discontinuation and Clinical Disease Activity Index (CDAI) response rates at 1 year. Analyses were adjusted for patient, disease and treatment characteristics, including lines of therapy and accounted for competing risk. Results We included 31 846 treatment courses: 17 522 TNFi, 2775 ABA, 3863 IL-6i and 7686 JAKi. Adjusted analyses of overall discontinuation were similar across all treatments. The main single reason of stopping treatment was ineffectiveness. Compared with TNFi, JAKi were less often discontinued for ineffectiveness (adjusted HR (aHR) 0.75, 95% CI 0.67 to 0.83), as was IL-6i (aHR 0.76, 95% CI 0.67 to 0.85) and more often for adverse events (aHR 1.16, 95% CI 1.03 to 1.33). Adjusted CDAI response rates at 1 year were similar between TNFi, JAKi and IL-6i and slightly lower for ABA. Conclusion The adjusted overall drug discontinuation and 1 year response rates of JAKi and IL-6i were similar to those observed with TNFi. Compared with TNFi, JAKi were more often discontinued for adverse events and less for ineffectiveness, as were IL-6i.

18 August 2020 in Rheumatology
Verified
Journal Article
Closed access
DCDelphine S Courvoisier
Delphine S Courvoisier
KCKatarina Chatzidionysiou
Katarina Chatzidionysiou
DMDenis Mongin
Denis Mongin
KLKim Lauper
Kim Lauper
XMXavier Mariette
Xavier Mariette
AFAxel Finckh
Axel Finckh
Objectives: RF and ACPA are used as diagnostic tools and their presence has been associated with clinical response to some biologic DMARDs (bDMARDs) in RA. This study compared the impact of seropositivity on drug discontinuation and effectiveness of bDMARDs in patients with RA, using head-to-head comparisons in a real-world setting. Methods: We conducted a pooled analysis of 16 observational RA registries. Inclusion criteria were a diagnosis of RA, initiation of treatment with rituximab (RTX), abatacept (ABA), tocilizumab (TCZ) or TNF inhibitors (TNFis) and available information on RF and/or ACPA status. Drug discontinuation was analysed using Cox regression, including drug, seropositivity, their interaction, adjusting for concomitant and past treatments and patient and disease characteristics and accounting for country and calendar year of bDMARD initiation. Effectiveness was analysed using the Clinical Disease Activity Index evolution over time. Results: Among the 27 583 eligible patients, the association of seropositivity with drug discontinuation differed across bDMARDs (P for interaction <0.001). The adjusted hazard ratios for seropositive compared with seronegative patients were 1.01 (95% CI 0.95, 1.07) for TNFis, 0.89 (0.78, 1.02)] for TCZ, 0.80 (0.72, 0.88) for ABA and 0.70 (0.59, 0.84) for RTX. Adjusted differences in remission and low disease activity rates between seropositive and seronegative patients followed the same pattern, with no difference in TNFis, a small difference in TCZ, a larger difference in ABA and the largest difference in RTX (Lundex remission difference +5.9%, low disease activity difference +11.6%). Conclusion: Seropositivity was associated with increased effectiveness of non-TNFi bDMARDs, especially RTX and ABA, but not TNFis.